Temporal trends in small-cell lung cancer trials registered on ClinicalTrials.gov: a cross-sectional analysis (1996–2025) Authors: Jian Cui, Jianhua Chen, Hongming Zhang Published: 2026 ABSTRACT AbstractBackgroundSmall-cell lung cancer (SCLC) has undergone important therapeutic advances in recent years, including the incorporation of programmed death-ligand 1 (PD-L1) inhibitors into first-line treatment for extensive-stage disease and the emergence of novel therapies for relapsed disease. Whether the characteristics of registered SCLC clinical trials have evolved in parallel with these advances remains incompletely understood. This study aimed to characterize temporal changes in the design, sponsorship, and geographic distribution of interventional SCLC trials registered on ClinicalTrials.gov between 1996 and 2025.MethodsIn this cross-sectional study of ClinicalTrials.gov registry records, interventional studies with start dates between January 1, 1996, and December 31, 2025, were identified using the condition terms “Small-Cell Lung Cancer” or “SCLC”. Two oncologists independently screened eligible records according to predefined inclusion and exclusion criteria, with disagreements resolved by a third reviewer. Trial characteristics, including phase, enrollment size, masking, allocation, funding source, geographic participation, and recruitment status, were extracted. Categorical variables were summarized descriptively and compared across six 5-year start-year intervals using Pearson χ2 or Fisher’s exact tests, as appropriate. The Cochran-Armitage trend test was used to evaluate temporal trends in industry sponsorship.ResultsA total of 825 interventional SCLC trials were included, of which 97.7% evaluated therapeutic interventions. Phase 2 studies predominated (55.7%), 48.4% enrolled fewer than 50 participants, and 91.5% were open-label. Among trials reporting allocation, 69.0% were randomized. Trial activity was concentrated in the United States and China and increased markedly after 2016, with 63.3% of all included trials initiated between 2016 and 2025. Although non-industry funding remained the most common overall, the proportion of industry-sponsored trials increased significantly over time, from 10.3% during 1996–2000 to 37.8% during 2021–2025 (trend P<0.0001).ConclusionsRegistered SCLC clinical trial activity has expanded substantially during the past decade, reflecting renewed therapeutic development in this disease. Nevertheless, the trial portfolio remains dominated by early- and mid-phase, open-label studies with relatively small enrollment. These findings highlight the need for larger, internationally collaborative, confirmatory trials and more robust evidence generation to translate emerging therapeutic advances into improved outcomes for patients with SCLC.Keywords: Small-cell lung cancer (SCLC), ClinicalTrials.gov, temporal trends, geographic distribution, cross-sectional study Highlight box Key findings • SCLC clinical trial activity has expanded substantially over the past decade, accompanied by increasing industry involvement. However, the overall trial landscape remains dominated by relatively small, early- and mid-phase, open-label studies, highlighting persistent gaps in confirmatory evidence generation. What is known and what is new? • The treatment landscape of SCLC has evolved rapidly with the introduction of immunotherapy and novel therapeutic agents, but corresponding changes in the clinical trial landscape have not been well characterized. • This study provides a comprehensive three-decade overview of registered SCLC trials, demonstrating marked growth in trial activity since 2016, increasing industry sponsorship, and geographic concentration of clinical research, particularly in the United States and China. What is the implication, and what should change now? • Future SCLC research should prioritize larger, adequately powered confirmatory trials, greater international collaboration, and broader geographic participation to strengthen the evidence base and translate therapeutic advances into meaningful improvements in patient outcomes. Introduction Small-cell lung cancer (SCLC) represents approximately 10–15% of lung cancers and remains a major contributor to lung cancer mortality (1). Biologically, SCLC is a highly aggressive neuroendocrine malignancy characterized by rapid cellular proliferation, early metastatic dissemination, and a pronounced initial sensitivity to cytotoxic therapy followed by frequent relapse. Among patients diagnosed with limited-stage (LS) disease—defined as tumor confined to one hemithorax and regional lymph nodes and amenable to definitive radiotherapy—long-term outcomes remain limited despite curative-intent multimodality therapy. In contrast, most patients present with extensive-stage (ES) disease and have poor survival outcomes (1). For more than three decades, platinum-based doublet chemotherapy has served as the therapeutic backbone for SCLC management. In LS-SCLC, concurrent chemoradiotherapy remains the standard curative-intent approach. For ES-SCLC, platinum-etoposide chemotherapy in combination with immune checkpoint blockade has become a standard first-line option following phase III evidence demonstrating improved overall survival with the addition of programmed death-ligand 1 (PD-L1) inhibitors (2,3). Despite high initial response rates across disease stages, the clinical course of SCLC is marked by frequent and rapid relapse, with subsequent resistance to salvage therapies and limited effective treatment options (1). Central nervous system involvement represents a common and clinically significant pattern of failure in SCLC, leading to the integration of prophylactic cranial irradiation (PCI) into treatment paradigms for selected patients. Contemporary evidence continues to evaluate the role of PCI in the era of routine brain imaging and evolving systemic therapies (4). Over the past decade, the therapeutic landscape of SCLC has undergone its most substantial changes in several decades. For ES-SCLC, the addition of PD-L1 inhibitors to platinum-etoposide chemotherapy has become the standard first-line treatment following randomized phase III trials demonstrating improved overall survival (1). More recently, treatment strategies for LS-SCLC have also evolved with advances in multimodality therapy and immunotherapy (1). Furthermore, novel agents targeting delta-like ligand 3 (DLL3), including the bispecific T-cell engager tarlatamab, have demonstrated encouraging activity in relapsed SCLC, reflecting renewed therapeutic interest in this historically challenging disease. Despite these advances, long-term outcomes remain poor, underscoring the continued need for innovative and efficiently designed clinical trials. In parallel with these therapeutic developments, the global SCLC clinical trial landscape has expanded considerably. However, it remains unclear whether registered clinical trials have evolved in step with the changing treatment paradigm or continue to be characterized by traditional development patterns, such as predominance of early-phase, small, open-label studies. Understanding how trial characteristics have changed over time may provide insight into the maturity of the SCLC research ecosystem and help identify opportunities for improving future clinical trial design. Therefore, we conducted a cross-sectional analysis of interventional SCLC trials registered on ClinicalTrials.gov between January 1, 1996, and December 31, 2025, to characterize temporal trends in trial activity and design and to evaluate whether the evolution of registered trials has paralleled recent advances in SCLC therapeutics. Methods Data source and study identification We downloaded records for clinical studies registered on ClinicalTrials.gov by searching the condition terms “Small-Cell Lung Cancer” or “SCLC”, restricting results to interventional studies with start dates between January 1, 1996, and December 31, 2025. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study did not require institutional review board approval or informed consent because it used de-identified, publicly available registry data. Eligibility screening Two oncologists independently screened records for eligibility. Discrepancies were resolved by a third oncologist. Trials enrolling multiple solid tumors were excluded unless primarily focused on SCLC (e.g., lung neuroendocrine carcinoma or predominantly SCLC cohorts). Trials without therapeutic interventions were excluded. ClinicalTrials.gov assigns a unique National Clinical Trial (NCT) identifier to each registered study. Multiple updates or protocol amendments associated with the same NCT identifier were considered a single study. During screening, study titles, NCT identifiers, sponsors, interventions, enrollment information, and study descriptions were reviewed to identify potential duplicate registrations or multiple records referring to the same underlying trial. When duplicate records were identified, only the primary registration was retained for analysis. Study size The study included all interventional SCLC trials registered on ClinicalTrials.gov that met the predefined eligibility criteria and had study start dates between January 1, 1996, and December 31, 2025. Therefore, the study size was determined by the number of eligible registry records available during the study period rather than by a priori sample size calculation. Variables Eight trial dimensions were extracted: (I) phase; (II) number of arms (if available); (III) sample size; (IV) masking; (V) allocation; (VI) funding source; (VII) geography; and (VIII) recruitment status (if available). Statistical analysis Categorical variables were summarized as counts and percentages. Missing fields were excluded from the relevant analyses with denominators adjusted accordingly. Pearson chi-square test or one-sample proportion test was used to compare different categorical variables. Trials were grouped by start year into six 5-year intervals (1996–2000, 2001–2005, 2006–2010, 2011–2015, 2016–2020, 2021–2025). Comparisons across time intervals used Pearson χ2 tests (or Fisher’s exact tests when indicated by small expected cell counts). The Cochran-Armitage trend test assessed linear trends in the proportion of industry-sponsored trials across ordered intervals. Two-sided P<0.05 was considered statistically significant. Analyses were performed using Python. Analyses were conducted using available-case data. For each variable, trials with missing information were excluded from the corresponding analysis, and denominators were adjusted accordingly. Because registry data are subject to incomplete reporting, the potential influence of non-random missingness was considered when interpreting the findings. Results Studies identified A total of 7,629 records were retrieved from ClinicalTrials.gov for interventional studies with start dates between January 1, 1996, and December 31, 2025. After excluding non-SCLC studies, 1,473 trials remained. Following exclusion of multi-tumor trials not primarily focused on SCLC, 857 trials remained. After excluding trials without therapeutic interventions, 825 interventional SCLC trials comprised the final analytic cohort (Figure 1). Among included trials, 97.7% listed treatment as the primary purpose. Flow diagram of study selection. SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer. Trial characteristics Geographic distribution Among trials with geographic information (n=754), trial conduct was concentrated in East Asia and North America, with additional participation from Europe and other regions (categories not mutually exclusive due to multinational trials) (Figure 2). At the country level, the United States and China represented the largest contributors [45.9% (346/754) listed U.S. sites and 39.0% (294/754) listed China sites]. A subset of trials was multinational across both countries [5.8% (44/754)], whereas 40.1% (302/754) were U.S.-only and 33.2% (250/754) were China-only. Global geographic distribution heatmap. Phase distribution Among trials with phase information (n=802), phase 2 trials predominated [55.7% (447/802)], followed by phase 3 [16.2% (130/802)], phase 1 [14.0% (112/802)], and phase 1/2 [11.6% (93/802)]. Phase 2/3 [1.6% (13/802)] and phase 4 [0.9% (7/802)] were uncommon. Phase distribution differed significantly across 5-year intervals (P<0.0001; Table 1). Table 1Characteristics of small-cell lung cancer trials (N=825)CharacteristicNumberDenominator%P valuePhase<0.0001 Phase 111280214.0 Phase 1/phase 29380211.6 Phase 244780255.7 Phase 2/phase 3138021.6 Phase 313080216.2 Phase 478020.9Enrollment size (participants)<0.0001 <5039481448.4 50–10019481423.8 >10022681427.8Masking<0.0001 Open-label73380191.5 Single78010.9 Double238012.9 Triple98011.1 Quadruple298013.6Allocation<0.0001 Randomized28741669.0 Nonrandomized12941631.0Funding source<0.0001 Industry26282531.8 NIH/other U.S. federal438255.2 All others (institution/individual/network)52082563.0Geographic participation (not mutually exclusive)– United States34675445.9 China29475439.0 Other15875421.0 Characteristics of small-cell lung cancer trials (N=825) Enrollment size Among trials with non-missing enrollment (n=814), 48.4% (394/814) enrolled <50 participants, 23.8% (194/814) enrolled 50–100, and 27.8% (226/814) enrolled >100 participants. Enrollment category distribution differed significantly across 5-year intervals (P<0.0001). Masking and allocation Among trials with available masking information (n=801), 733 (91.5%) were open-label studies without masking, whereas only 68 (8.5%) reported any form of masking (P<0.0001). Among trials with allocation reported as either randomized or nonrandomized (n=416), 287 (69.0%) were randomized and 129 (31.0%) were nonrandomized (P<0.0001). Funding and temporal trends in industry sponsorship Overall funding was most commonly categorized as “all other” sources (institutions/individuals/networks) [63.0% (520/825)], followed by industry [31.8% (262/825)] and NIH/other U.S. federal [5.2% (43/825)]. Funding composition differed significantly across 5-year intervals (P<0.0001). Across 5-year intervals, the proportion of industry-sponsored trials within each interval increased from 10.3% (4/39) in 1996–2000 to 37.8% (122/323) in 2021–2025. A Cochran-Armitage trend test confirmed a statistically significant increasing trend in industry sponsorship across ordered intervals (trend P<0.0001) (Figure 3). Small-cell lung cancer trial initiation and industry sponsorship by 5-year intervals. Bars show the proportion of all included trials initiated in each interval; the shaded portion indicates industry-sponsored trials. Temporal distribution of trial initiation The distribution of trial start years shifted toward more recent periods: 4.7% (39/825) in 1996–2000, 9.1% (75/825) in 2001–2005, 12.6% (104/825) in 2006–2010, 10.3% (85/825) in 2011–2015, followed by a sharp increase to 24.1% (199/825) in 2016–2020 and 39.2% (323/825) in 2021–2025 (Figure 3). Discussion In this cross-sectional analysis of 825 interventional SCLC trials registered on ClinicalTrials.gov between 1996 and 2025, we identified several notable patterns in the global SCLC clinical research landscape. First, trial activity accelerated substantially after 2016, with nearly two-thirds of all included trials initiated during the past decade. Second, phase 2 studies predominated, whereas phase 3 and phase 4 trials comprised a relatively small proportion of the portfolio. Third, most trials were small to moderate in size and conducted in an open-label fashion. Finally, industry sponsorship increased steadily over time and represented more than one-third of newly initiated trials in the most recent 5-year interval. The marked growth in trial initiation after 2016 likely reflects renewed therapeutic momentum in SCLC. This increase coincided with the establishment of immune checkpoint inhibitors combined with platinum-etoposide chemotherapy as the standard first-line treatment for ES disease following positive phase III trials. These advances marked the first meaningful improvement in first-line treatment outcomes after decades of reliance on platinum-based chemotherapy, which had yielded only modest long-term survival benefits. The subsequent expansion of the therapeutic pipeline, including immunotherapy and emerging targeted approaches, likely stimulated increased academic interest and commercial investment in SCLC drug development. Consistent with this evolving landscape, the temporal increase in industry-sponsored trials observed in our study suggests that recent therapeutic advances were accompanied by greater translational and pharmaceutical investment in SCLC research. Despite this increase in trial volume, our findings indicate that the SCLC research ecosystem remains heavily weighted toward mid-phase development, with more than half of included studies categorized as phase 2 and fewer than one in six as phase 3. This pattern is aligned with the broader clinical reality that SCLC remains biologically aggressive and prone to early relapse, with many investigational strategies failing to translate into durable survival improvements in confirmatory settings. The relative scarcity of phase 4 trials further suggests that postmarketing evaluation and real-world evidence generation remain comparatively underdeveloped in SCLC, potentially limiting understanding of effectiveness and safety in broader patient populations. Enrollment patterns also highlight structural features of SCLC research. Nearly half of trials enrolled fewer than 50 participants, and fewer than 30% enrolled more than 100 participants. Small sample sizes may limit statistical power, increase susceptibility to type II error, and reduce generalizability in a clinically aggressive malignancy where attrition and rapid clinical deterioration can constrain trial completion. The predominance of open-label designs—observed in the vast majority of trials with masking information—likely reflects practical and ethical considerations common in oncology trials, particularly when endpoints include time-to-event measures and when blinding is difficult for multimodality regimens. Nevertheless, among trials reporting allocation methods, a majority were randomized, suggesting that investigators frequently incorporated randomization when feasible. Geographically, SCLC trials were concentrated in East Asia and North America, with the United States and China serving as the primary country-level contributors. The marked increase in trial activity in China during the past decade likely reflects several concurrent developments. Regulatory reforms initiated by the former China Food and Drug Administration (now the National Medical Products Administration) substantially improved the efficiency of clinical trial approval and accelerated the development of innovative oncology therapies. Policies promoting international harmonization of drug regulation, acceptance of overseas clinical data, and expedited review pathways have created a more favorable environment for early-phase oncology research and multinational drug development. Together with expanding clinical research infrastructure and increasing investment from both domestic and multinational pharmaceutical companies, these reforms have contributed to the rapid growth of oncology clinical trials in China. Similarly, the increasing proportion of industry-sponsored trials likely reflects renewed commercial interest in SCLC following decades of limited therapeutic progress. The successful introduction of PD-L1 inhibitors combined with platinum-etoposide chemotherapy into first-line treatment for ES-SCLC renewed confidence that meaningful improvements in patient outcomes could be achieved. More recently, the development of novel therapeutic approaches—including DLL3-directed therapies such as tarlatamab and other emerging targeted agents—has further expanded the development pipeline (5). These advances have likely encouraged greater pharmaceutical investment in SCLC and contributed to the sustained increase in industry-sponsored clinical trials observed in our study. Although our analysis cannot establish causal relationships, the temporal association between therapeutic advances and increased trial activity is consistent with the evolving landscape of SCLC drug development. Our study has several implications. First, the observed increase in trial activity and industry sponsorship indicates renewed therapeutic interest in SCLC, a malignancy historically characterized by limited innovation beyond platinum-based chemotherapy (1). Second, the dominance of early- and mid-phase studies highlights an ongoing need for well-powered confirmatory trials capable of establishing new standards of care, particularly as immune checkpoint inhibitors and other emerging modalities evolve (2,3). Third, the relatively small size and open-label design of many trials underscore opportunities to strengthen methodological rigor and improve evidence quality. Future research efforts may benefit from international collaboration, platform approaches, biomarker-driven strategies, and enhanced integration of postapproval evidence generation. The present study focused on broad characteristics of trial design and conduct rather than the specific therapeutic modalities being investigated. Consequently, we did not classify interventions according to treatment class or mechanism of action. Future registry-based analyses incorporating detailed categorization of investigational therapies—including chemotherapy, radiotherapy, immunotherapy, biomarker-driven approaches, antibody-drug conjugates, and DLL3-directed agents such as bispecific T-cell engagers—could provide additional insight into how the therapeutic focus of SCLC research has evolved. Likewise, evaluating trends in multicenter and international collaboration, as well as the distribution of trial activity across sponsors and institutions, would further enhance understanding of the changing SCLC clinical research landscape. In addition, several variables contained incomplete registry information. Although analyses were performed using available-case data, missing information may not have occurred completely at random. Reporting completeness may differ according to study period, funding source, geographic region, or other trial characteristics, potentially introducing bias into descriptive comparisons. Consequently, findings based on variables with incomplete reporting should be interpreted with appropriate caution. Several limitations should be acknowledged. First, this study was based exclusively on ClinicalTrials.gov, one of the largest international clinical trial registries, but it does not include all SCLC trials conducted worldwide. Studies registered exclusively in other national or regional registries may not have been captured, introducing potential selection bias and limiting the generalizability of our findings to the global SCLC research landscape. Second, registry-based analyses are susceptible to classification bias because study characteristics depend on the accuracy and completeness of investigator-reported information. Reporting practices and data completeness may vary across sponsors, geographic regions, and study periods, potentially influencing the observed distributions of trial characteristics. Third, registration bias should be considered, as not all studies are registered prospectively and registration requirements have evolved over time, particularly following changes in international regulatory and publication policies (6). Finally, because this was a cross-sectional analysis of registry records, we were unable to assess study quality, publication status, trial outcomes, or the clinical impact of individual studies. Accordingly, our findings should be interpreted as describing trends among trials registered on ClinicalTrials.gov rather than the entirety of the global SCLC clinical trial ecosystem. Conclusions From 1996 to 2025, interventional SCLC trial activity increased markedly—particularly after 2016—accompanied by statistically significant growth in industry sponsorship and notable shifts in geographic participation. Despite this expansion, the research landscape remains dominated by phase 2, small-scale, open-label studies, with relatively few confirmatory late-phase or postmarketing trials. Together, these findings underscore the need to prioritize more rigorous, adequately powered, and globally representative confirmatory studies to translate early-phase signals into durable clinical advances and ultimately improve outcomes for patients with this aggressive malignancy. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Footnotes Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1161/coif). The authors have no conflicts of interest to declare. References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1161/prf Supplementary Materials The article’s supplementary files as